4D Molecular's One-Shot Eye Therapy Delivers Two-Year Winbenzinga_article·Jul 20 at 08:05 AMFDMT+3.08%
4D Molecular Therapeutics reports positive 2-year PRISM Phase 2b data, 78–87% reduction in injectionsTradingView·Jul 20 at 07:33 AMFDMT+3.08%
4D Molecular Therapeutics posts corporate presentation highlighting 4D-150 retina gene therapy programPUBT·Jul 18 at 02:51 PMFDMT+3.08%
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population | FDMT Stock NewsStockTitan·Jul 18 at 06:15 AMFDMT+3.08%
4DMT Announces New Employment Inducement Grants | FDMT Stock NewsStockTitan·Jul 17 at 07:05 AMFDMT+3.08%
4D Molecular Therapeutics CEO David Kirn sells USD 739,829 in common sharesPUBT·Jul 14 at 04:05 PMFDMT+3.08%
4D Molecular Therapeutics Chief Legal Officer Scott Bizily disposes of 6,566 common shares valued at $91,924PUBT·Jul 2 at 03:08 PMFDMT+3.08%
4D Molecular Therapeutics to present 2-year PRISM Phase 2b data for 4D-150 gene therapy in neovascular AMD at ASRS 2026PUBT·Jun 30 at 03:05 PMFDMT+3.08%
4D Molecular Therapeutics completes enrollment for Phase 3 4D-150 wet AMD trial 4FRONT-2PUBT·Jun 29 at 07:00 AMFDMT+3.08%
